Skip to main content
Clinical Trials/NCT02857062
NCT02857062
Completed
N/A

An Open Label, In-use Tolerance Study in Babies and Children With Dry/Atopic and Very Dry/Atopic Skin, to Evaluate the Acceptability and Skin Tolerability of E45 Eczema Repair Emollient for the Treatment of Atopic or Eczema Prone Skin

Reckitt Benckiser Healthcare (UK) Limited0 sites34 target enrollmentNovember 23, 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
Atopic Dermatitis / Eczema
Sponsor
Reckitt Benckiser Healthcare (UK) Limited
Enrollment
34
Primary Endpoint
Parental Assessment of Cutaneous Tolerance
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The investigation will evaluate, under dermatological control, the cutaneous in-use tolerance of E45 Eczema Repair Emollient with two or three times daily application, over a period of two weeks on children and babies with dry/atopic and very dry/atopic skin.

Detailed Description

The investigation is an open label, in-use cutaneous tolerance investigation in children and babies with dry/atopic and very dry/atopic skin, to evaluate the acceptability and skin tolerability of E45 Eczema Repair Emollient. The investigation will be an 'at home' user investigation where the test product will be applied by the parent/legal guardian to a pre-defined test site (arm or leg) between 2 to 3 times daily, consecutively for 14 days.

Registry
clinicaltrials.gov
Start Date
November 23, 2016
End Date
February 2, 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • be female or male
  • be a child aged from ≥3 years to \< 12 years or a baby aged from ≥3 months to \< 36 months at screening
  • be phototype I - IV (Fitzpatrick Phototyping Scale)
  • have skin that is dry/atopic or very dry/atopic (confirmed by the Dermatologist in consultation with the parent/legal guardian)
  • have mild atopic eczema (as confirmed by the Dermatologist in consultation with the parent/legal guardian) but not undergoing steroid treatment for the condition
  • have only few or no pigmentation on the selected test site
  • be in general good health and mental condition
  • In addition the parent/legal guardian must:
  • Both parents in case of shared custody/legal guardian will provide written informed consent for their child/baby to participate in the investigation (children aged 6 years and above, capable of understanding the investigation after it has been explained to them, will be asked to provide assent. Pre-schoolers (2-5 years) will be allowed to express a level of assent verbally relating to their ability to do so)
  • agree to attend the investigation centre, with the child/baby, on the predefined days

Exclusion Criteria

  • have chronic or acute skin diseases, except atopic eczema on any part of the body
  • have an active flare up of atopic eczema on any sites of the body at screening
  • known allergy or sensitivity to cosmetic products and/or any ingredients of the investigational product.
  • any systemic illness that would impact on the subjects safety or wellbeing and/or affect the response of the skin or the interpretation of the test results at screening (Day -14 to -7)
  • receiving the following topical or systemic treatments at baseline (Day 0);
  • anti-inflammatory and/or anti-histamines during the previous week
  • cough suppressants and/or topical or inhaled corticosteroids during the previous 2 weeks
  • retinoids and/or immunosuppressants during the previous 6 months
  • have diabetes, acute cardiac and circulatory diseases, HIV, hepatitis
  • participation in other studies/investigations on any part of the body during the last 4 weeks

Outcomes

Primary Outcomes

Parental Assessment of Cutaneous Tolerance

Time Frame: 14 Days

The dermatologist will ask the parent/legal guardian to provide their assessment of tolerance by asking the parent/legal guardian if they considered the product to be well tolerated by their child/baby's skin

Global Assessment of Cutaneous Tolerance

Time Frame: 14 Days

The dermatologist will make a 'global assessment' of tolerance for each subject based on reported product use/compliance

Cutaneous Tolerance

Time Frame: 14 Days

The total irritancy score (Erythema score + Oedema score + Papules score + Vesicles score) for each subject from baseline to end of study as observed by the investigation Dermatologist.

Similar Trials